Please login to the form below

Not currently logged in
Email:
Password:

fasiglifam

This page shows the latest fasiglifam news and features for those working in and with pharma, biotech and healthcare.

Takeda drops prostate cancer drug in phase III

Takeda drops prostate cancer drug in phase III

The Japanese company also dropped diabetes candidate fasiglifam earlier this year, but it has a good crop of other products at, or nearing, commercialisation.

Latest news

  • Omontys terminal as Takeda switches off support Omontys terminal as Takeda switches off support

    Meanwhile, Takeda has had a bad run of luck with its late-stage pipeline of late, dropping diabetes candidate fasiglifam earlier this year.

  • Takeda pipeline hit by fasiglifam failure Takeda pipeline hit by fasiglifam failure

    Takeda pipeline hit by fasiglifam failure. Diabetes candidate had been set for a 2015 launch. ... Takeda has suffered a major pipeline setback after deciding to terminate development of fasiglifam, a candidate therapy for diabetes that had been scheduled

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics